ClinicalTrials.gg
CompletedNCT03326193Updated Jul 31, 2025Results posted

A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

A Phase 2 interventional study of Niraparib and Bevacizumab in Ovarian Neoplasms, sponsored by Tesaro, Inc.. Completed at 29 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-31.

Sponsored by Tesaro, Inc. (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
105
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies testing niraparib in Ovarian Neoplasms — 9 open to participants now, 14 under way, 2 of them phase 3. niraparib · Ovarian Neoplasms.

Enrollment
12th of 44
105 · median 41
Started
2017
with 3 others
Phase 2
18 of 44
5 open now
Registered
11th of 44
by date
Lead sponsor
11 of 44
Tesaro, Inc.

Among the 44 studies testing niraparib in Ovarian Neoplasms, this one is the 12th largest by enrollment, is one of 4 that started in 2017, is one of 18 in phase 2, and was the 11th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

9 of the 44 studies testing niraparib in Ovarian Neoplasms are open now, in 10 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About niraparib

niraparib: first FDA approval 2017 (ZEJULA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing niraparib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

Niraparib is an oral inhibitor of poly adenosine diphosphate-ribose polymerase (PARP)-1 and PARP-2. This study will evaluate safety and efficacy of niraparib combined with bevacizumab as maintenance treatment in participants with advanced (stage IIIB-IV) ovarian cancer, fallopian tube cancer, or primary peritoneal cancer following front-line platinum-based chemotherapy with bevacizumab. Eligible participants who achieve complete response (CR), partial response (PR), or no evidence of disease (NED) following treatment with platinum-based chemotherapy in addition to bevacizumab will be enrolled in the study and will receive maintenance treatment with niraparib (for up to 3 years) combined with bevacizumab (for up to 10 months during the maintenance phase or up to a total of 15 months inclusive of the approximately 5 months of bevacizumab received with chemotherapy) or until disease progression, unacceptable toxicity, participant withdrawal, Investigator's decision, or death, whichever comes first. Participants who have not progressed after 3 years of niraparib maintenance treatment may continue with niraparib beyond 3 years if they are benefiting from treatment, upon consultation with Sponsor.

03

Conditions studied

  • Ovarian Neoplasms

Browse trials for

Keywords

  • Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor
  • Ovarian Cancer
  • Primary Peritoneal carcinoma
  • Fallopian Tube
  • Vascular endothelial growth factor (VEGF) inhibitor
  • Bevacizumab
  • Niraparib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be female, be greater than equal to (>=) 18 years of age, be able to understand the study procedures, and agree to participate in the study by providing written .
  • Participants must have newly diagnosed International Federation of Gynecology and Obstetrics (FIGO) Stage IIIB to IV epithelial ovarian, fallopian tube, or peritoneal cancer and have recovered from debulking surgery.
  • Participants must have high-grade serous or endometrioid or high-grade predominantly serous or endometrioid histology, regardless of homologous recombination deficiency (HRD) or germline breast cancer susceptibility gene (gBRCA) mutation status. Participants with non mucinous epithelial ovarian cancer and gBRCA mutation are eligible.
  • Participants must have completed front-line, platinum-based chemotherapy with CR, PR, or NED and have first study treatment dose within 12 weeks of the first day of the last cycle of chemotherapy:
  • a. A platinum-based regimen must have consisted of a minimum of 6 and a maximum of 9 treatment cycles. Participants who discontinued platinum-based therapy early as a result of non hematologic toxicity specifically related to the platinum regimen (ie, neurotoxicity or ) are eligible if they have received a minimum of 4 cycles of the platinum regimen.
  • b. IV, intraperitoneal, or platinum-based chemotherapy is allowed; for weekly therapy, 3 weeks is considered 1 cycle. Interval debulking is allowed.
  • Participants must have received, prior to enrollment, a minimum of 3 cycles of bevacizumab in combination with the last 3 cycles of platinum-based chemotherapy. Participants who undergo interval debulking surgery are eligible if they have received only 2 cycles of bevacizumab in combination with the last 3 cycles of platinum-based chemotherapy.
  • Participant must have had 1 attempt at optimal debulking surgery.
  • Participant must have either CA-125 in the normal range or CA-125 decrease by more than 90% during front-line therapy that is stable for at least 7 days (ie, no increase > 15% from nadir).
  • Participant must have adequate organ function.
  • Participant must have an (ECOG) score of 0 or 1.
  • Participant must have normal blood pressure or well-controlled hypertension.
  • Participant must agree to complete patient-reported outcome (PROs) (Functional Assessment of Cancer Therapy-Ovarian Symptom Index [FOSI] questionnaire) throughout the study, including after study treatment discontinuation.
  • Participant must be able to take oral medication.
  • Participant must agree to undergo tumor HRD testing at screening. The tumor sample must be confirmed to be available during the screening period and submitted after the participant has been enrolled. Participants do not have to wait for the HRD test result to be enrolled. If is not available for testing, the participant must agree to undergo a fresh biopsy.
  • Participant of must have a negative serum or urine pregnancy test (beta human chorionic gonadotropin) within 72 hours prior to receiving the first dose of study treatment.
  • Participants must be , free from menses for > 1 year, surgically sterilized, or willing to use adequate to prevent pregnancy or must agree to abstain from activities that could result in pregnancy throughout the study, starting with enrollment through 180 days after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Participants with ovarian tumors of non-epithelial origin (eg, germ cell tumor) or any low grade tumors.
  • Participants with cardiovascular disease (eg, significant cardiac conduction abnormalities, uncontrolled hypertension, myocardial infarction, cardiac arrhythmia or unstable angina \< 6 months to enrollment, (NYHA) Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, Grade II or greater peripheral vascular disease, and history of cerebrovascular accident (CVA) within 6 months).
  • Participants with gastrointestinal disorders or abnormalities that would interfere with absorption of study treatment.
  • History of bowel obstruction, including sub-occlusive disease, related to the underlying disease or history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscesses. Evidence of rectosigmoid involvement by pelvic examination or bowel involvement on computed tomography (CT) scan or clinical symptoms of bowel obstruction.
  • Participant has proteinuria as demonstrated by urine protein:creatinine ratio >= 1.0 at screening or urine dipstick for proteinuria ≥ 2 (participants discovered to have >=2 proteinuria on dipstick at baseline should undergo a 24-hour urine collection and must demonstrate \< 2 gram (g) of protein in 24 hours to be eligible).
  • Participant has any known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML).
  • Participant has received treatment previously with a PARP inhibitor.
  • Other than ovarian cancer, the participant has been diagnosed or treated for invasive cancer less than 5 years prior to study enrollment. Participants with cervical carcinoma in situ, non melanomatous skin cancer, and ductal carcinoma in situ definitively treated are allowed.
  • Participant is considered a poor medical risk due to a serious, uncontrolled medical disorder, non malignant systemic disease, or active, uncontrolled infection.
  • Participant has known to PARP inhibitors or (VEGF inhibitors.
  • Participant is at increased bleeding risk due to concurrent conditions (eg, major injuries or surgery within the past 28 days prior to start of study treatment, history of CVA, , subarachnoid hemorrhage, or clinically significant hemorrhage within the past 3 months).
  • Participant is (participants with splenectomy are allowed).
  • Participant has known, active hepatic disease (ie, or C).
  • Participant has a prolongation > 480 milliseconds (ms) at screening. If a participant has a prolonged QT interval and the prolongation is deemed to be due to a pacemaker upon Investigator evaluation (ie, the participant otherwise has no cardiac abnormalities), then the participant may be eligible to participate in the study following discussion with the Medical Monitor.
  • Participant is pregnant, or expecting to conceive children while receiving study drug or for 180 days after the last dose of study drug ; additionally, female participant should not breastfeed during treatment with niraparib and for 30 days after receipt of the last dose due to the potential for serious adverse reactions from niraparib in breastfed infants
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    Participants receiving niraparib+ bevacizumab

    Participants will be administered bevacizumab 15 milligram per kilogram (mg/kg) via a 30 minute (min) intravenous (IV) infusion on Day 1 of each 21-day cycle. Niraparib will be administered orally once a day continuously throughout each 21-day cycle (84-day cycle after amendment 2). On Day 1 of each cycle, niraparib will be administered upon completion of bevacizumab infusion. The starting dose of niraparib will be based on the participant's Baseline actual body weight or platelet count.

    Drug: Niraparib · Biological: Bevacizumab

Interventions

  • Niraparib will be administered orally once a day continuously throughout each 21 day cycle (84-day cycle after amendment 2). The starting dose of niraparib will be based on the participant's Baseline actual body weight or platelet count. Participants with a Baseline actual body weight of greater than equal to (\>=) 77 kg and Baseline platelet count of \>=150,000/ microliter (μL) will take 300 mg/day (3X100mg) at each dose administration. Participants with a Baseline actual body weight of less than (\<) 77 kg and/or Baseline platelet count of \<150,000/μL will take 200 mg (2X100 mg) at each dose administration.

    Also known as: ZEJULA

  • BiologicalBevacizumab

    Maintenance bevacizumab 15 mg/kg will be administered via a 30-minute IV infusion on Day 1 of every 21-day cycle in the absence of progressive disease (PD), unacceptable toxicity, participant withdrawal, Investigator's decision, or death. Bevacizumab will be administered for up to 10 months during the maintenance phase or up to a total of 15 months inclusive of approximately 5 months of bevacizumab received with chemotherapy.

    Also known as: Avastin

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) Rate

    PFS rate at 18 months is defined as the percentage of participants who have not progressed or died within 18 months after niraparib combined with bevacizumab treatment initiation. Progression was assessed by response evaluation criteria in solid tumors (RECIST) version (v) 1.1 criteria per Investigator assessment and defined as a 20 percent (%) increase in the sum of the diameter of target lesions or unequivocal progression of existing non-target lesions. Survival rate is the percentage of participants without progression assessed by RECIST v1.1 or death by the landmark timepoint. Confidence intervals was constructed using exact method.

    Time frame: At 18 months

Secondary outcomes

  1. Progression Free Survival (PFS) by RECIST v 1.1

    PFS was defined as the time from treatment initiation with niraparib combined with bevacizumab to the earlier date of assessment of progression, as assessed by RECIST v1.1 criteria, based on Investigator assessment, or death by any cause in the absence of progression.

    Time frame: Up to end of study (approximately 79 months)

  2. Overall Survival (OS)

    OS was defined as the date of initiation of niraparib treatment in combination with bevacizumab to the date of death by any cause.

    Time frame: Up to end of study (approximately 79 months)

  3. RECIST or Cancer Antigen (CA)-125 Progression Free Survival

    RECIST or CA-125 progression-free survival is defined as the time from initiation of niraparib treatment in combination with bevacizumab to the earliest date of progression assessed by RECIST v1.1 or CA-125 progression or death by any cause. CA-125 progression is defined as participants with elevated CA-125 pretreatment and normalization of CA-125 that must show evidence of CA-125 ≥ 2 × upper limit of normal (ULN) on 2 occasions at least 1 week apart OR elevated CA-125 pretreatment that never normalizes and must show evidence of CA-125 ≥ 2 × the nadir value on 2 occasions at least 1 week apart OR elevated CA-125 in the normal range pretreatment that must show evidence of CA-125 ≥ 2 × ULN on 2 occasions at least 1 week apart.

    Time frame: Up to end of study (approximately 79 months)

  4. Change From Baseline (CFB) in Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI)

    FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants responded to their symptom experience over the past 7 days using a 5-point Likert scale scored from "not at all" (0) to "very much" (4). FOSI score was calculated as sum of item scores multiplied by 8 divided by number of items answered. The FOSI score ranged from 0 (severely symptomatic) to 32 (asymptomatic). A higher score indicated a better quality of life (QoL). Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).

    Time frame: Baseline (Day 1), Cycles 3, 5, 7, 9, 13, 17, 21, 25, 29 (Each Cycle was of 21 days) and end of treatment (70 months)

  5. Time to First Subsequent Therapy (TFST)

    TFST was defined as the date of initiation of niraparib treatment in combination with bevacizumab treatment in the current study to the start date of the first subsequent anticancer therapy.

    Time frame: Up to end of study (approximately 79 months)

  6. Time to Second Subsequent Therapy (TSST)

    TSST was defined as the date of initiation of treatment of niraparib in combination with bevacizumab treatment in the current study to the start date of the second subsequent anticancer therapy.

    Time frame: Up to end of study (approximately 79 months)

  7. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs), Non-serious TEAEs and Treatment-emergent Serious Adverse Events (TESAEs)

    Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. TEAEs is any AE that occurred for the first time after at least 1 dose of study treatment administration and until treatment duration. TEAEs which were not serious were considered as non-serious TEAEs. TESAE is defined as any untoward medical occurrence that, at any dose may result in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity or is congenital anomaly/birth defect or any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system. Percentages are rounded off to the nearest decimal point.

    Time frame: Up to end of treatment (70 months)

  8. Number of Participants With TEAEs Leading to Niraparib Treatment Discontinuation

    AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. TEAE is any AE that occurred for the first time after at least 1 dose of study treatment administration. AEs were coded using the MedDRA coding system.

    Time frame: Up to end of treatment (70 months)

  9. Number of Participants With TEAEs Leading to Niraparib Dose Reductions

    AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. TEAE is any AE that occurred for the first time after at least 1 dose of study treatment administration. AEs were coded using the MedDRA coding system.

    Time frame: Up to end of treatment (70 months)

  10. Number of Participants With AEs of Special Interest (AESI)

    AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AESIs of scientific and medical concern related to the treatment were monitored, and rapidly communicated by investigator to sponsor. AEs were coded using the MedDRA coding system.

    Time frame: Up to end of treatment (70 months)

  11. Change From Baseline (CFB) in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    Blood pressures (DBP and SBP) were measured after resting for at least 5 minutes in a supine or semi-recumbent position. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).

    Time frame: Baseline (Day 1) and end of treatment (70 months)

  12. Change From Baseline (CFB) in Pulse Rate

    Pulse Rate was measured after resting for at least 5 minutes in a supine or semi-recumbent position. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).

    Time frame: Baseline (Day 1) and end of treatment (70 months)

  13. Change From Baseline (CFB) in Temperature

    Temperature was measured after resting for at least 5 minutes in a supine or semi-recumbent position. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).

    Time frame: Baseline (Day 1) and end of treatment (70 months)

  14. Number of Participants Who Used Concomitant Medications

    Any permitted concomitant medication(s), including non-prescription medication(s) and herbal product(s), taken during the study were recorded.

    Time frame: Up to end of treatment (70 months)

  15. Change From Baseline (CFB) in Hematology Parameters: Basophils, Eosinophil, Leukocytes, Platelets, Lymphocytes, Monocytes and Neutrophils

    Blood samples were collected for the assessment of change from Baseline in hematology parameters. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).

    Time frame: Baseline (Day 1) and end of treatment (70 months)

  16. Change From Baseline (CFB) in Hematology Parameter: Hemoglobin (Hb)

    Blood samples were collected for the assessment of change from Baseline in hematology parameter. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).

    Time frame: Baseline (Day 1) and end of treatment (70 months)

  17. Change From Baseline (CFB) in Hematology Parameter: Erythrocyte Mean Corpuscular Volume (MCV)

    Blood samples were collected for the assessment of change from Baseline in hematology parameter. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).

    Time frame: Baseline (Day 1) and end of treatment (70 months)

  18. Change From Baseline (CFB) in Clinical Chemistry Parameters: Urea Nitrogen, Glucose, Calcium, Chloride, Sodium, Magnesium and Potassium

    Blood samples were collected for the assessment of change from Baseline in clinical chemistry parameters. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).

    Time frame: Baseline (Day 1) and end of treatment (70 months)

  19. Change From Baseline (CFB) in Clinical Chemistry Parameters: Bilirubin and Creatinine

    Blood samples were collected for the assessment of change from Baseline in clinical chemistry parameters. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).

    Time frame: Baseline (Day 1) and end of treatment (70 months)

  20. Change From Baseline (CFB) in Clinical Chemistry Parameters: Albumin and Protein

    Blood samples were collected for the assessment of change from baseline in clinical chemistry parameters. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).

    Time frame: Baseline (Day 1) and end of treatment (70 months)

  21. Change From Baseline (CFB) in Clinical Chemistry Parameters: Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT)

    Blood samples were collected for the assessment of change from baseline in clinical chemistry parameters. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).

    Time frame: Baseline (Day 1) and end of treatment (70 months)

07

Results

Posted Jan 19, 2022

Participant flow

Participant flow — Overall Study
MilestoneNiraparib + Bevacizumab
Started105
Completed70
Not completed35
Withdrew: Sponsor decision35

Outcome measures

PrimaryProgression Free Survival (PFS) Rate

PFS rate at 18 months is defined as the percentage of participants who have not progressed or died within 18 months after niraparib combined with bevacizumab treatment initiation. Progression was assessed by response evaluation criteria in solid tumors (RECIST) version (v) 1.1 criteria per Investigator assessment and defined as a 20 percent (%) increase in the sum of the diameter of target lesions or unequivocal progression of existing non-target lesions. Survival rate is the percentage of participants without progression assessed by RECIST v1.1 or death by the landmark timepoint. Confidence intervals was constructed using exact method.

Time frame:
At 18 months
Reported as:
Number · Percentage of participants
Progression Free Survival (PFS) Rate
Percentage of participantsNiraparib + Bevacizumab
Progression Free Survival (PFS) Rate62 (51.9 to 71.2)
SecondaryProgression Free Survival (PFS) by RECIST v 1.1

PFS was defined as the time from treatment initiation with niraparib combined with bevacizumab to the earlier date of assessment of progression, as assessed by RECIST v1.1 criteria, based on Investigator assessment, or death by any cause in the absence of progression.

Time frame:
Up to end of study (approximately 79 months)
Reported as:
Median · Months
Progression Free Survival (PFS) by RECIST v 1.1
MonthsNiraparib + Bevacizumab
Progression Free Survival (PFS) by RECIST v 1.119.6 (16.56 to 25.07)
SecondaryOverall Survival (OS)

OS was defined as the date of initiation of niraparib treatment in combination with bevacizumab to the date of death by any cause.

Time frame:
Up to end of study (approximately 79 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsNiraparib + Bevacizumab
Overall Survival (OS)61.1 (44.88 to NA)
SecondaryRECIST or Cancer Antigen (CA)-125 Progression Free Survival

RECIST or CA-125 progression-free survival is defined as the time from initiation of niraparib treatment in combination with bevacizumab to the earliest date of progression assessed by RECIST v1.1 or CA-125 progression or death by any cause. CA-125 progression is defined as participants with elevated CA-125 pretreatment and normalization of CA-125 that must show evidence of CA-125 ≥ 2 × upper limit of normal (ULN) on 2 occasions at least 1 week apart OR elevated CA-125 pretreatment that never normalizes and must show evidence of CA-125 ≥ 2 × the nadir value on 2 occasions at least 1 week apart OR elevated CA-125 in the normal range pretreatment that must show evidence of CA-125 ≥ 2 × ULN on 2 occasions at least 1 week apart.

Time frame:
Up to end of study (approximately 79 months)
Reported as:
Median · Months
RECIST or Cancer Antigen (CA)-125 Progression Free Survival
MonthsNiraparib + Bevacizumab
RECIST or Cancer Antigen (CA)-125 Progression Free Survival16.9 (13.27 to 22.05)
SecondaryChange From Baseline (CFB) in Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI)

FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants responded to their symptom experience over the past 7 days using a 5-point Likert scale scored from "not at all" (0) to "very much" (4). FOSI score was calculated as sum of item scores multiplied by 8 divided by number of items answered. The FOSI score ranged from 0 (severely symptomatic) to 32 (asymptomatic). A higher score indicated a better quality of life (QoL). Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).

Time frame:
Baseline (Day 1), Cycles 3, 5, 7, 9, 13, 17, 21, 25, 29 (Each Cycle was of 21 days) and end of treatment (70 months)
Reported as:
Mean · Scores on scale
Change From Baseline (CFB) in Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI)
Scores on scaleNiraparib + Bevacizumab
Baseline (Day 1)25.7 ± 3.79
CFB to Cycle 3-1.4 ± 4.30
CFB to Cycle 5-1.7 ± 3.89
CFB to Cycle 7-0.3 ± 3.09
CFB to Cycle 9-1.1 ± 3.74
CFB to Cycle 13-1.1 ± 4.25
CFB to Cycle 17-0.7 ± 3.39
CFB to Cycle 21-0.6 ± 3.77
CFB to Cycle 250.1 ± 3.73
CFB to Cycle 290.7 ± 3.40
CFB to End of Treatment (70 months)-2.0 ± 5.21
SecondaryTime to First Subsequent Therapy (TFST)

TFST was defined as the date of initiation of niraparib treatment in combination with bevacizumab treatment in the current study to the start date of the first subsequent anticancer therapy.

Time frame:
Up to end of study (approximately 79 months)
Reported as:
Median · Months
Time to First Subsequent Therapy (TFST)
MonthsNiraparib + Bevacizumab
Time to First Subsequent Therapy (TFST)17.5 (14.55 to 20.73)
SecondaryTime to Second Subsequent Therapy (TSST)

TSST was defined as the date of initiation of treatment of niraparib in combination with bevacizumab treatment in the current study to the start date of the second subsequent anticancer therapy.

Time frame:
Up to end of study (approximately 79 months)
Reported as:
Median · Months
Time to Second Subsequent Therapy (TSST)
MonthsNiraparib + Bevacizumab
Time to Second Subsequent Therapy (TSST)38.6 (30.55 to 55.85)
SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs), Non-serious TEAEs and Treatment-emergent Serious Adverse Events (TESAEs)

Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. TEAEs is any AE that occurred for the first time after at least 1 dose of study treatment administration and until treatment duration. TEAEs which were not serious were considered as non-serious TEAEs. TESAE is defined as any untoward medical occurrence that, at any dose may result in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity or is congenital anomaly/birth defect or any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system. Percentages are rounded off to the nearest decimal point.

Time frame:
Up to end of treatment (70 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs), Non-serious TEAEs and Treatment-emergent Serious Adverse Events (TESAEs)
Percentage of participantsNiraparib + Bevacizumab
TEAEs100
Non-serious TEAEs100
TESAEs30.5
SecondaryNumber of Participants With TEAEs Leading to Niraparib Treatment Discontinuation

AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. TEAE is any AE that occurred for the first time after at least 1 dose of study treatment administration. AEs were coded using the MedDRA coding system.

Time frame:
Up to end of treatment (70 months)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Leading to Niraparib Treatment Discontinuation
ParticipantsNiraparib + Bevacizumab
Number of Participants With TEAEs Leading to Niraparib Treatment Discontinuation46
SecondaryNumber of Participants With TEAEs Leading to Niraparib Dose Reductions

AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. TEAE is any AE that occurred for the first time after at least 1 dose of study treatment administration. AEs were coded using the MedDRA coding system.

Time frame:
Up to end of treatment (70 months)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Leading to Niraparib Dose Reductions
ParticipantsNiraparib + Bevacizumab
Number of Participants With TEAEs Leading to Niraparib Dose Reductions81
SecondaryNumber of Participants With AEs of Special Interest (AESI)

AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AESIs of scientific and medical concern related to the treatment were monitored, and rapidly communicated by investigator to sponsor. AEs were coded using the MedDRA coding system.

Time frame:
Up to end of treatment (70 months)
Reported as:
Count of participants · Participants
Number of Participants With AEs of Special Interest (AESI)
ParticipantsNiraparib + Bevacizumab
New malignancies other than Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)4
MDS/AML Event2
SecondaryChange From Baseline (CFB) in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

Blood pressures (DBP and SBP) were measured after resting for at least 5 minutes in a supine or semi-recumbent position. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).

Time frame:
Baseline (Day 1) and end of treatment (70 months)
Reported as:
Mean · Millimeter of mercury (mmHg)
Change From Baseline (CFB) in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Millimeter of mercury (mmHg)Niraparib + Bevacizumab
SBP: Baseline (Day 1)129.7 ± 15.87
SBP: CFB to End of Treatment (70 months)2.8 ± 21.70
DBP: Baseline (Day 1)78.2 ± 9.30
DBP: CFB to End of Treatment (70 months)0.3 ± 11.17
SecondaryChange From Baseline (CFB) in Pulse Rate

Pulse Rate was measured after resting for at least 5 minutes in a supine or semi-recumbent position. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).

Time frame:
Baseline (Day 1) and end of treatment (70 months)
Reported as:
Mean · Beats/minute
Change From Baseline (CFB) in Pulse Rate
Beats/minuteNiraparib + Bevacizumab
Baseline (Day 1)80.6 ± 11.40
CFB to End of Treatment (70 months)4.3 ± 13.12
SecondaryChange From Baseline (CFB) in Temperature

Temperature was measured after resting for at least 5 minutes in a supine or semi-recumbent position. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).

Time frame:
Baseline (Day 1) and end of treatment (70 months)
Reported as:
Mean · Celsius
Change From Baseline (CFB) in Temperature
CelsiusNiraparib + Bevacizumab
Baseline (Day 1)36.59 ± 0.297
CFB to End of Treatment (70 months)-0.01 ± 0.439
SecondaryNumber of Participants Who Used Concomitant Medications

Any permitted concomitant medication(s), including non-prescription medication(s) and herbal product(s), taken during the study were recorded.

Time frame:
Up to end of treatment (70 months)
Reported as:
Count of participants · Participants
Number of Participants Who Used Concomitant Medications
ParticipantsNiraparib + Bevacizumab
Number of Participants Who Used Concomitant Medications100
SecondaryChange From Baseline (CFB) in Hematology Parameters: Basophils, Eosinophil, Leukocytes, Platelets, Lymphocytes, Monocytes and Neutrophils

Blood samples were collected for the assessment of change from Baseline in hematology parameters. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).

Time frame:
Baseline (Day 1) and end of treatment (70 months)
Reported as:
Mean · Giga cells per liter (10^9 cells/L)
Change From Baseline (CFB) in Hematology Parameters: Basophils, Eosinophil, Leukocytes, Platelets, Lymphocytes, Monocytes and Neutrophils
Giga cells per liter (10^9 cells/L)Niraparib + Bevacizumab
Basophils: Baseline (Day 1)0.025 ± 0.0320
Basophils: CFB to End of Treatment (70 months)0.008 ± 0.0385
Eosinophil: Baseline (Day 1)0.168 ± 0.3071
Eosinophil: CFB to End of Treatment (70 months)-0.028 ± 0.3245
Leukocytes: Baseline (Day 1)5.523 ± 1.5398
Leukocytes: CFB to End of Treatment (70 months)0.660 ± 3.9571
Platelets: Baseline (Day 1)219.810 ± 79.5186
Platelets: CFB to End of Treatment (70 months)-6.585 ± 74.0943
Lymphocytes: Baseline (Day 1)1.694 ± 0.6216
Lymphocytes: CFB to End of Treatment (70 months)0.152 ± 2.1904
Monocytes: Baseline (Day 1)0.492 ± 0.2137
Monocytes: CFB to End of Treatment (70 months)0.007 ± 0.1819
Neutrophils: Baseline (Day 1)3.135 ± 1.1369
Neutrophils: CFB to End of Treatment (70 months)0.197 ± 1.6063
SecondaryChange From Baseline (CFB) in Hematology Parameter: Hemoglobin (Hb)

Blood samples were collected for the assessment of change from Baseline in hematology parameter. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).

Time frame:
Baseline (Day 1) and end of treatment (70 months)
Reported as:
Mean · Grams per liter (g/L)
Change From Baseline (CFB) in Hematology Parameter: Hemoglobin (Hb)
Grams per liter (g/L)Niraparib + Bevacizumab
Baseline (Day 1)116.800 ± 10.0234
CFB to End of Treatment (70 months)4.787 ± 14.4303
SecondaryChange From Baseline (CFB) in Hematology Parameter: Erythrocyte Mean Corpuscular Volume (MCV)

Blood samples were collected for the assessment of change from Baseline in hematology parameter. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).

Time frame:
Baseline (Day 1) and end of treatment (70 months)
Reported as:
Mean · Femtoliters (fL)
Change From Baseline (CFB) in Hematology Parameter: Erythrocyte Mean Corpuscular Volume (MCV)
Femtoliters (fL)Niraparib + Bevacizumab
Baseline (Day 1)97.560 ± 7.0779
CFB to End of Treatment (70 months)0.093 ± 5.4536
SecondaryChange From Baseline (CFB) in Clinical Chemistry Parameters: Urea Nitrogen, Glucose, Calcium, Chloride, Sodium, Magnesium and Potassium

Blood samples were collected for the assessment of change from Baseline in clinical chemistry parameters. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).

Time frame:
Baseline (Day 1) and end of treatment (70 months)
Reported as:
Mean · Millimoles per liter (mmol/L)
Change From Baseline (CFB) in Clinical Chemistry Parameters: Urea Nitrogen, Glucose, Calcium, Chloride, Sodium, Magnesium and Potassium
Millimoles per liter (mmol/L)Niraparib + Bevacizumab
Urea Nitrogen: Baseline (Day 1)5.681 ± 1.7222
Urea Nitrogen: CFB to End of Treatment (70 months)0.375 ± 2.1948
Glucose: Baseline (Day 1)5.996 ± 2.3156
Glucose: CFB to End of Treatment (70 months)-0.073 ± 2.8001
Calcium: Baseline (Day 1)2.377 ± 0.0872
Calcium: CFB to End of Treatment (70 months)0.018 ± 0.1005
Chloride: Baseline (Day 1)102.747 ± 2.9885
Chloride: CFB to End of Treatment (70 months)-0.536 ± 3.4272
Sodium: Baseline (Day 1)139.467 ± 2.8184
Sodium: CFB to End of Treatment (70 months)-0.298 ± 2.7192
Magnesium: Baseline (Day 1)0.764 ± 0.1024
Magnesium: CFB to End of Treatment (70 months)0.017 ± 0.0977
Potassium: Baseline (Day 1)4.206 ± 0.3860
Potassium: CFB to End of Treatment (70 months)0.031 ± 0.4891
SecondaryChange From Baseline (CFB) in Clinical Chemistry Parameters: Bilirubin and Creatinine

Blood samples were collected for the assessment of change from Baseline in clinical chemistry parameters. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).

Time frame:
Baseline (Day 1) and end of treatment (70 months)
Reported as:
Mean · Micromoles per liter (umol/L)
Change From Baseline (CFB) in Clinical Chemistry Parameters: Bilirubin and Creatinine
Micromoles per liter (umol/L)Niraparib + Bevacizumab
Bilirubin: Baseline (Day 1)6.242 ± 2.8546
Bilirubin: CFB to End of Treatment (70 months)1.168 ± 3.2660
Creatinine: Baseline (Day 1)65.577 ± 16.3865
Creatinine: CFB to End of Treatment (70 months)9.339 ± 16.4405
SecondaryChange From Baseline (CFB) in Clinical Chemistry Parameters: Albumin and Protein

Blood samples were collected for the assessment of change from baseline in clinical chemistry parameters. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).

Time frame:
Baseline (Day 1) and end of treatment (70 months)
Reported as:
Mean · Grams per liter (g/L)
Change From Baseline (CFB) in Clinical Chemistry Parameters: Albumin and Protein
Grams per liter (g/L)Niraparib + Bevacizumab
Albumin: Baseline (Day 1)41.629 ± 3.3748
Albumin: CFB to End of Treatment (70 months)0.926 ± 3.1902
Protein: Baseline (Day 1)70.619 ± 5.0676
Protein: CFB to End of Treatment (70 months)0.309 ± 4.5744
SecondaryChange From Baseline (CFB) in Clinical Chemistry Parameters: Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT)

Blood samples were collected for the assessment of change from baseline in clinical chemistry parameters. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).

Time frame:
Baseline (Day 1) and end of treatment (70 months)
Reported as:
Mean · International units per Liter (IU/L)
Change From Baseline (CFB) in Clinical Chemistry Parameters: Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT)
International units per Liter (IU/L)Niraparib + Bevacizumab
AST: Baseline (Day 1)24.619 ± 12.0043
AST: CFB to End of Treatment (70 months)5.117 ± 20.0863
ALT: Baseline (Day 1)23.590 ± 13.4241
ALT: CFB to End of Treatment (70 months)4.362 ± 19.3484

Adverse events

Collected over All-cause mortality was collected up to approximately 79 months (end of study) and treatment emergent non-serious adverse events and serious adverse events were collected up to 70 months (end of treatment).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Niraparib + Bevacizumab56/105 (53.3%)32/105 (30.5%)105/105 (100%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventNiraparib + Bevacizumab
Platelet count decreasedInvestigations8/105
ThrombocytopeniaBlood and lymphatic system disorders6/105
Small intestinal obstructionGastrointestinal disorders2/105
Chest painGeneral disorders2/105
HypertensionVascular disorders2/105
AnaemiaBlood and lymphatic system disorders1/105
PancytopeniaBlood and lymphatic system disorders1/105
DysphagiaGastrointestinal disorders1/105
Lower gastrointestinal haemorrhageGastrointestinal disorders1/105
PyrexiaGeneral disorders1/105
Most frequent other events
Showing 10 of 83
Most frequent other events
EventNiraparib + Bevacizumab
FatigueGeneral disorders72/105
NauseaGastrointestinal disorders65/105
HeadacheNervous system disorders59/105
HypertensionVascular disorders57/105
AnaemiaBlood and lymphatic system disorders55/105
ProteinuriaRenal and urinary disorders43/105
Platelet count decreasedInvestigations42/105
ConstipationGastrointestinal disorders40/105
ArthralgiaMusculoskeletal and connective tissue disorders38/105
ThrombocytopeniaBlood and lymphatic system disorders36/105

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Niraparib + Bevacizumab
Mean59.7 ± 10.33
Sex: Female, Male
Sex: Female, Male(Participants)Niraparib + Bevacizumab
Female105
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Niraparib + Bevacizumab
White91
Black or African American4
Asian3
American Indian or Alaska Native1
Unknown6
08

Study locations

29 sites
  • GSK Investigational Site
    Mobile, Alabama 36604, United States
  • GSK Investigational Site
    Anchorage, Alaska 99508, United States
  • GSK Investigational Site
    Mesa, Arizona 85284, United States
  • GSK Investigational Site
    Burbank, California 91505, United States
  • GSK Investigational Site
    Los Angeles, California 90095, United States
  • GSK Investigational Site
    Fort Myers, Florida 33908, United States
  • GSK Investigational Site
    St. Petersburg, Florida 33705, United States
  • GSK Investigational Site
    Kansas City, Kansas 66205, United States
  • GSK Investigational Site
    Detroit, Michigan 48201, United States
  • GSK Investigational Site
    Detroit, Michigan 48202, United States
  • GSK Investigational Site
    Jackson, Mississippi 39216, United States
  • GSK Investigational Site
    Columbia, Missouri 65212, United States
  • GSK Investigational Site
    Kansas City, Missouri 64132, United States
  • GSK Investigational Site
    Lebanon, New Hampshire 03756, United States
  • GSK Investigational Site
    Englewood, New Jersey 07631, United States
  • GSK Investigational Site
    Morristown, New Jersey 07962-1956, United States
  • GSK Investigational Site
    Summit, New Jersey 07962-1956, United States
  • GSK Investigational Site
    Albany, New York 12208, United States
  • GSK Investigational Site
    Rochester, New York 14642, United States
  • GSK Investigational Site
    Asheville, North Carolina 28816, United States
  • GSK Investigational Site
    Columbus, Ohio 43214, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73104, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15224, United States
  • GSK Investigational Site
    Providence, Rhode Island 02905, United States
  • GSK Investigational Site
    Chattanooga, Tennessee 37403, United States
  • GSK Investigational Site
    Kingsport, Tennessee 37660, United States
  • GSK Investigational Site
    Nashville, Tennessee 37203, United States
  • GSK Investigational Site
    Fort Worth, Texas 76104, United States
  • GSK Investigational Site
    Seattle, Washington 98109, United States
09

References and documents

Publications

  • Hardesty MM, Krivak TC, Wright GS, Hamilton E, Fleming EL, Belotte J, Keeton EK, Wang P, Gupta D, Clements A, Gray HJ, Konecny GE, Moore RG, Richardson DL. OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. Gynecol Oncol. 2022 Aug;166(2):219-229. doi: 10.1016/j.ygyno.2022.05.020. Epub 2022 Jun 9. PubMed 35690498 ↗
  • Hardesty MM, Krivak TC, Wright GS, Hamilton E, Fleming EL, Belotte J, Gorman S, Compton N, Clements A, Gray HJ, Konecny GE, Moore RG, Richardson DL. A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO. Gynecol Oncol. 2025 Aug;199:96-102. doi: 10.1016/j.ygyno.2025.06.014. Epub 2025 Jul 1. PubMed 40602355 ↗
  • Thaker PH, Areli Calderon Boyle T, Burns S, Lim J, Hartman J, Kalilani LV, Schilder JM, Hurteau JA, Golembesky AK. Characteristics and real-world outcomes of patients with epithelial ovarian cancer who received niraparib plus bevacizumab first-line maintenance therapy in the COMB1NE study. Int J Gynecol Cancer. 2024 Dec 2;34(12):1924-1931. doi: 10.1136/ijgc-2024-005611. PubMed 39244209 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Dec 2020, 36 months.

Results were first posted in Jan 2022, 1 year after primary completion.

Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 36 months is close to that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2017
First posted
Oct 31, 2017
StartActual
Dec 12, 2017
Primary completionActual
Dec 24, 2020
CompletionActual
Jul 12, 2024
Results first posted
Jan 19, 2022
Last update
Jul 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03326193
Lead sponsor
Tesaro, Inc.
Responsible party
Sponsor
First posted
Oct 31, 2017
Start date
Dec 12, 2017
Primary completion
Dec 24, 2020
Completion
Jul 12, 2024
Results posted
Jan 19, 2022
Last update
Jul 31, 2025

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Niraparib · Bevacizumab

Start the discussion